BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 3412332)

  • 1. Binding and activation of C4 and C3 on the red cell surface by non-complement enzymes.
    Kirschfink M; Borsos T
    Mol Immunol; 1988 May; 25(5):505-12. PubMed ID: 3412332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator.
    Gigli I; Fujita T; Nussenzweig V
    Proc Natl Acad Sci U S A; 1979 Dec; 76(12):6596-600. PubMed ID: 293746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Covalent association of C3b with C4b within C5 convertase of the classical complement pathway.
    Takata Y; Kinoshita T; Kozono H; Takeda J; Tanaka E; Hong K; Inoue K
    J Exp Med; 1987 Jun; 165(6):1494-507. PubMed ID: 3495629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
    Kozlov LV; Shibanova ED; Zinchenko AA
    Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formation of high affinity C5 convertase of the classical pathway of complement.
    Rawal N; Pangburn MK
    J Biol Chem; 2003 Oct; 278(40):38476-83. PubMed ID: 12878586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
    Medof ME; Kinoshita T; Nussenzweig V
    J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
    Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of the classical pathway C3 convertase (EAC4b2a) by proteolytic enzymes.
    Loos M; Heinz HP
    Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():67-74. PubMed ID: 6375257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The low C5 convertase activity of the C4A6 allotype of human complement component C4.
    Kinoshita T; Dodds AW; Law SK; Inoue K
    Biochem J; 1989 Aug; 261(3):743-8. PubMed ID: 2803239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of human complement components C4 and C3 with amines or chaotropic ions. Evidence of a functional and structural change that provides uncleaved C4 and C3 with properties of their soluble activated froms, C4b and C3b.
    von Zabern I; Nolte R; Vogt W
    Scand J Immunol; 1981; 13(5):413-31. PubMed ID: 6171865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of action of the C4 nephritic factor. Deregulation of the classical pathway of C3 convertase.
    Gigli I; Sorvillo J; Mecarelli-Halbwachs L; Leibowitch J
    J Exp Med; 1981 Jul; 154(1):1-12. PubMed ID: 7019379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
    Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
    Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of radiographic contrast media on complement components C3 and C4: generation of C3b-like C3 and C4b-like C4.
    von Zabern I; Przyklenk H; Vogt W; Sachsenheimer W
    Int J Immunopharmacol; 1983; 5(6):503-13. PubMed ID: 6607225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mouse complement component C4 is devoid of classical pathway C5 convertase subunit activity.
    Ebanks RO; Isenman DE
    Mol Immunol; 1996 Feb; 33(3):297-309. PubMed ID: 8649451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A model system for the study of the assembly and regulation of human complement C3 convertase (classical pathway).
    Thielens NM; Colomb MG
    Eur J Immunol; 1986 Jun; 16(6):617-22. PubMed ID: 3487454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single arginine to tryptophan interchange at beta-chain residue 458 of human complement component C4 accounts for the defect in classical pathway C5 convertase activity of allotype C4A6. Implications for the location of a C5 binding site in C4.
    Ebanks RO; Jaikaran AS; Carroll MC; Anderson MJ; Campbell RD; Isenman DE
    J Immunol; 1992 May; 148(9):2803-11. PubMed ID: 1573269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation and deregulation of the fluid-phase classical pathway C3 convertase.
    Gigli I; Sorvillo J; Halbwachs-Mecarelli L
    J Immunol; 1985 Jul; 135(1):440-4. PubMed ID: 3158705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement receptor is an inhibitor of the complement cascade.
    Iida K; Nussenzweig V
    J Exp Med; 1981 May; 153(5):1138-50. PubMed ID: 6910481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mechanism of activation of the alternative pathway of complement by cell-bound C4b.
    Farries TC; Steuer KL; Atkinson JP
    Mol Immunol; 1990 Nov; 27(11):1155-61. PubMed ID: 2247091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.